Pediatric-Onset Multiple Sclerosis
Information from clinical trials in children with MS is furthering understanding and improving treatment options for this rare presentation.
Multiple sclerosis (MS) most commonly presents in adulthood; however, in 3% to 5% of patients with MS, the first clinical attack occurs prior to age 18 years.1 The first demyelinating attack in childhood is termed an acquired demyelinating syndrome (ADS), which may be a monophasic illness or a first attack of a relapsing demyelinating disorder, such as MS. The proportion of children with ADS who have MS ranges from 15% to 45%.2 Pediatric-onset MS (POMS) follows a relapsing-remitting course at onset, with fewer than 2% of pediatric patients presenting with a primary progressive form of MS.1,3 More frequent relapses in early disease stages compared with adults is characteristic of POMS.4 Children tend to have more complete recovery after attacks, and disability accumulation is slower compared with adult-onset MS. Secondary progressive disability usually does not occur until approximately 20 years after onset.1,3 Treatment is largely based on data obtained from clinical trials in adult patients; however, there are 2 recent randomized clinical trials performed in children that provide high-quality efficacy and safety data. In this review, we discuss the clinical features, neuroimaging, disease course, and available treatments for children with MS.
Incidence of POMS is 0.07 to 2.9 per 100,000 children, several times lower than in adults.3,5 Incidence rises during adolescence with a median age of first attack between 11 and 13 years.6 Onset prior to age 10 years accounts for less than 1% of all cases. There is a female-to-male ratio as high as 4.5 to 1 in those age 12 years and up. In POMS with onset under age 12 years, the ratio appears to be more even.1,3
Most immunopathologic studies have been completed in adults with MS. In a study comparing 10 children with POMS with 10 adults with MS and 10 healthy control subjects of all ages, patients with POMS had increased numbers of circulating memory T cells producing interleukin (IL)-17 and a higher proliferative response to myelin peptides.7 (See also Immunopathogenesis of Multiple Sclerosis in this Issue)
Risk factors for POMS and adult-onset MS include having 1 or more HLA-DRB*15 alleles, Epstein-Barr virus (EBV) exposure, low serum vitamin D levels, obesity, and second-hand smoke exposure. HLA-DRB1*15 is the strongest genetic risk factor for MS. In a study of 266 children presenting with ADS, those with HLA-DRB*15 were more likely to be diagnosed with MS than controls (odds ratio [OR] = 2.7).8 A multinational study found that 86% of patients with POMS (108/125) were seropositive for remote EBV infection compared with 64% of matched controls, irrespective of geographic residence.9
Meta-analysis utilizing Mendelian randomization to estimate the causal association between low vitamin D and POMS found increasing vitamin D levels in serum decreased odds of POMS (OR = 0.72, 95% CI: 0.55-0.94; P = .02) after controlling for sex, genetic ancestry, HLA-DRB1*15, and more than 100 MS-risk variants.10 Vitamin D status may also influence disease activity. In a retrospective study of 110 people with POMS, every 10 ng/mL increase in adjusted 25-hydroxyvitamin D3 level was associated with a 34% decrease in relapse rate, highlighting the role of vitamin D supplementaion in routine care of those with POMS.11
Elevated body mass index (BMI) has also been associated with a higher risk of developing POMS. Obesity is believed to induce the Th17 response via an IL-6–dependent process eliciting an inflammatory response. Increased adiposity also leads to increased risk of vitamin D deficiency and decreased response to vitamin D supplementation.10
Finally, secondhand smoke exposure in a study of 81 patients with POMS compared with 216 children with mono-ADS showed that secondhand smoke exposure did not independently increase risk for MS, but when both secondhand smoke exposure and HLA-DRB*15:01 were combined, the odds of MS were significantly increased (OR = 3.7, 95% CI: 1.17-11.9).12
Clinical Features and Disease Course
The initial clinical presentation of POMS relates to the site of active demyelination and includes visual loss (acute optic neuritis), paresthesias, focal weakness, urinary symptoms, diplopia, or ataxia. Onset prior to age 10 years is more likely to manifest with brainstem involvement, polyfocal deficits, and encephalopathy.1,3 When encephalopathy is present, the diagnosis of acute disseminated encephalomyelitis (ADEM) is also considered and serial clinical and MRI observation is essential to determining whether a diagnosis of MS is appropriate. Seizures have also been reported as an initial presentation of POMS.1
Diagnosis of MS rests on the concept of dissemination of disease over time and dissemination to involve multiple areas of the CNS. More than 98% of patients with POMS have a relapsing-remitting disease course. In contrast to adults, primary progressive MS is extremely rare in children. Progressive neurologic impairment from onset in a child should prompt a comprehensive evaluation for other diagnoses such as mitochondrial disease, malignancies, or neurodegenerative disease.3 The early stage of MS in children is characterized by more frequent relapses than in adults with the annualized relapse rate (ARR) highest in the first 2 years after the initial attack. The relapse rate remains high for at least 5 years.4
Children with MS have lower disability scores early in the course of disease and on average do not experience significant ambulation deficits until 20 or more years after the initial attack. Patients with POMS generally take 10 years longer to convert to secondary progressive MS (SPMS) compared with adults. Due to the early age of onset, patients with POMS do reach SPMS on average 10 years earlier than those with adult-onset MS. Potential indicators for poor outcomes include a short interval (< 1 year) between the first 2 attacks, incomplete recovery after first attack, and brainstem involvement at onset.1,3
Although children with POMS have better physical disability outcomes compared with adults, significant cognitive impairment and fatigue are prominent features of POMS. In a study of 63 patients with POMS, approximately 31% fulfilled criteria for cognitive impairment and 73% reported fatigue.13 Another study of 68 patients with demyelinating disease found those with POMS were less likely to participate in vigorous (P = .009) or moderate (P = .048) physical activity than either patients with monophasic demyelination or healthy controls subjects.6 Further research is required to better identify the factors that limit engagement of those with POMS in vigorous activity.
The diagnosis of MS is based on clinical findings supported by MRI, cerebrospinal fluid (CSF) analysis, other laboratory results, and the exclusion of other diagnoses. The criteria for the diagnosis of MS were recently updated in 2017 with the following important revisions to the 2010 McDonald criteria.14
The 2017 McDonald criteria have been validated in a large pediatric cohort and shown to be comparable to the 2010 McDonald criteria.15 The ability to use CSF oligoclonal band findings to substitute for DIT in the 2017 criteria improved the diagnostic performance of the McDonald criteria in children.15
Neuroimaging plays an essential role in diagnosis and monitoring of POMS. The presence of 1 or more T2 hyperintense lesions characteristic of MS in 2 or more of the following areas of the CNS: periventricular, cortical or juxtacortical, infratentorial, or spinal cord demonstrates DIS. The simultaneous presence of enhancing and nonenhancing lesions at any time or new or newly enlarging T2 hyperintense or enhancing lesions on follow-up MRI demonstrates DIT.14
MRI is also used to monitor disease course. Compared with adults, children typically have a higher T2 lesion burden and experience a rapid accrual of new lesions in the first few years of the disease.1,2 The International Pediatric MS Study Group (IPMSSG) recommends children with MS have MRI scans every 6 months to monitor for new lesion accrual (Figure).16
In addition to conventional imaging designed to detect T2 bright and T1 hypointense lesions, quantitative analyses as well as other MR sequences provide insight into nonlesional pathology. Diffusion tensor imaging (DTI) has shown nonlesional widespread tissue disruption early in the disease course of POMS and even in monophasic demyelination; however, children appear to be less affected by these findings suggesting resilience in the maturing brain.17 These findings from DTI indicate that early demyelination that is not detected on conventional MRI might contribute to long-term outcomes and disease progression.
Acute and Chronic Treatment
The natural history of POMS, with high relapse rates and higher volume of brain lesions early in the disease, supports a role for prompt initiation of effective disease-modifying therapy. Guidance for treatment of POMS has largely been derived from clinical trials in adult patients, small case series, international consensus guidelines, and retrospective studies in children. Recent and ongoing clinical trials in the pediatric population are beginning to provide more rigorous efficacy and safety data.
For management of acute attacks, the standard therapy has been intravenous corticosteroids (eg, 30 mg/kg methylprednisolone up to 1,000 mg/day for 3 to 5 days) as first-line treatment.2 Intravenous corticosteroids accelerate the speed of recovery and reduce the number of actively enhancing lesions on MRI within a few days by modifying cytokine responses, reducing T-cell activation, reducing blood-brain permeability, and facilitating apoptosis of activated immune cells.2,18
For chronic disease management, traditional first-line therapies have included interferon β and glatiramer acetate. Both demonstrated a 29% to 34% reduction in ARR and decrease in new MRI lesion development in adult patients.19,20 Although there have been no treatment trials of interferon β in children, safety and tolerability have been demonstrated and published in retrospective reviews.18,21 In a study of 65 patients with POMS, the mean ARR decreased during treatment with either interferon β-1a (from 2.4 to 0.4) or glatiramer acetate (from 2.8 to 0.25).22 The limitations of retrospective data to inform on efficacy, however, must be considered.
A recent randomized, double-blind, placebo controlled 2-year trial compared oral fingolimod with weekly intramuscular interferon β-1a.23 Fingolimod was associated with a lower rate of relapse and less lesion accumulation on MRI, leading to approval by the Food and Drug Administration (FDA) and regulatory agencies in other countries for use of fingolimod to treat children with MS who are over age 10 years. For patients weighing less than 40 kg, a dose of 0.25 mg daily is used; the standard adult dose of 0.5 mg daily is used for those weighing more than 40 kg. Currently active clinical trials are evaluating efficacy and safety of dimethyl fumarate,24 teriflunomide, and alemtuzumab for POMS (Table).
Other treatments used to treat patients with POMS include natalizumab and rituximab. Natalizumab is a humanized monoclonal antibody against α4β1 and α4β7 integrins. Blocking these molecules prevents immune cells from crossing the blood-brain barrier.2,25 Proven efficacious in adults,24 the best data in pediatric patients is limited to prospective cohort studies. In a study of 55 patients with POMS using the adult dosing regimen of 300 mg intravenously every 4 weeks, ARR decreased to 0.1 ± 0.2 during treatment from an ARR of 2.4 ± 1.6 in the year preceding treatment (P < .001).26 Rituximab is a monoclonal antibody against CD20, a surface marker found on the majority of B cells. Rituximab has demonstrated a favorable safety profile in children27 and appears promising for use in neuroimmunologic diseases in children, including POMS.28
Another monoclonal antibody directed against CD20, ocrelizumab, has shown efficacy in treatment of adults29 with relapsing-remitting MS in 2 large clinical trials. Studies are being planned to investigate this medication for treatment of POMS.
Conclusion and Future Directions
In children, MS has a relapsing-remitting course with frequent relapses early in the disease but with minimal disability accrual. Cognitive impairment and continued cognitive decline, however, are of major concern and have the potential to negatively impact long-term quality of life. Effective therapy reduces relapse rates, brain lesions, and brain atrophy. The long-term benefit of early therapy remains to be seen, and close monitoring for potential therapy-mediated morbidities is necessary.
Because POMS is a rare disease, it is imperative for continued recruitment of patients with POMS into research studies and clinical trials on a multinational level to better understand the implications and management of POMS. Finally, given the chronic nature of this disease, emphasis on smooth transition of care from pediatric MS providers to adult MS providers is needed to ensure excellent continuity of care.
1. Renoux C, Vukusic S, Confavreux C. The natural history of multiple sclerosis with childhood onset. Clin Neurol Neurosurg. 2008;110(9):897-904.
2. Brenton JN, Banwell BL. Therapeutic approach to the management of pediatric demyelinating disease: multiple sclerosis and acute disseminated encephalomyelitis. Neurotherapeutics. 2016;13(1)84-95.
3. Waldman A, Ness J, Pohl D, et al. Pediatric multiple sclerosis: clinical features and outcome. Neurology. 2016;87(9):S74-S81.
4. Koch-Henriksen N, Sorenson PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet, 2010;9:520-532.
5. Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014;3(2):186-193.
6. Otallah S, Banwell B. Pediatric Multiple Sclerosis: an update. Curr Neurol Neurosci Rep. 2018;18(11):76.
7. Vargas-Lowy D, Kivisäkk P, Gandhi R, et al. Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol. 2013;146(3):176-184.
8. Disanto G, Magalhaes S, Handel AE, et al. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011; 76(9)781-786.
9. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: multinational observational study. Lancet Neurol. 2007;6(9):773-781.
10. Gianfrancesco MA, Stridh P, Rhead B, et al. Evidence for a causal relationship between low Vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017;88(17):1623-1629.
11. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67:618-624.
12. Lavery AM, Collins BN, Waldman AT, et al. The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal. 2018.
13. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010; 75(13)1134-1140.
14. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17:162-173.
15. Fadda G, Brown RA, Longoni G, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018; 2(3):191-204.
16. Banwell B, Arnold DL, Tilema J-M, et al. MRI in the evaluation of pediatric multiple sclerosis. Neurology. 2016;87 (9):S88-S96.
17. Vishwas MS, Healy BC, Pienaar R, Gorman MP, Grant PE, Chitnis T. Diffusion tensor analysis of pediatric multiple sclerosis and clinically isolated syndromes. AJNR Am J Neuroradiol. 2013;34(2)417-423.
18. Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother. 2005;11(4)505-520.
19. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4)655.
20. Johnson KP, Brooks BR, Cohen J a, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7)1268-1276.
21. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4)472-476.
22. Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4)420-424.
23. Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018; 379:1017-1027.
24. Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018;83:19-24.
25. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
26. Ghezzi A, Pozzilli C, Grimaldi L, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal. 2013;19(8):1106-1112.
27. Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US Neurology 2018;91(19):e1778-e1787.
28. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150.
29. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta 1a in relapsing multiple sclerosis. N Engl J Med. 2017; 376:221-234
Duriel I. Hardy, MD
Division of Neurology
Children’s Hospital of Philadelphia
Brenda L. Banwell, MD
Chief, Division of Neurology
Children’s Hospital of Philadelphia
The authors have no financial or other relationships relevant to this content to disclose.